Century Therapeutics, Inc. is a biotechnology company. The Company is focused on developing transformative allogeneic, pluripotent stem cells (iPSC)-derived natural killer (NK) and T cell therapies to create products for the treatment of both solid tumor and hematological malignancies. Its Allo-Evasion technology is intended to prevent rejection of cell products by the host immune system, and manufacturing capabilities intended to minimize product development and supply risk. The Company's pipeline includes CNTY-101, CNTY-103, CNTY-102 and CNTY-104. The Companyâ€™s lead product candidate, CNTY-101, is focused on targeting B-cell lymphoma. CNTY-103 is designed to treat glioblastoma. CNTY-102 is designed to further improve B-cell malignancy treatment. CNTY-104, is being developed to treat acute myeloid leukemia (AML). In addition to its programs, the Company is also actively engaged in a number of earlier stage discovery programs.
|Versant Venture Management LLC ||13,259,905||
|Bayer Aktiengesellschaft ||12,675,838||
|FUJIFILM Holdings Corporation ||6,955,207||
|Fidelity Management & Research Co. LLC ||6,312,260||
|Casdin Capital LLC ||3,206,380||
|SB Management Ltd. (AE) ||2,000,000||
|Osvaldo Flores ||1,321,719||
|Federated Global Investment Management Corp. ||1,164,094||
|RA Capital Management LP ||914,094||
|Avidity Partners Management LP ||739,269||
Sector Other Biotechnology & Medical Research
Connections : Century Therapeutics, Inc.